Vbi Vaccines Inc/bc

VBI Vaccines Inc. has completed its acquisition by K2 VBI Equity Trust, LLC, an affiliate of K2 HealthVentures LLC, and has emerged from creditor protection proceedings.

VBI Vaccines has provided an update on its restructuring proceedings, including a partial revocation order from the British Columbia Securities Commission to facilitate a transaction with K2 VBI Equity Trust.

VBI Vaccines Inc. has initiated restructuring proceedings under the Companies' Creditors Arrangement Act in Canada and Chapter 15 of the U.S. Bankruptcy Code, leading to its delisting from Nasdaq.

VBI Vaccines has commenced voluntary restructuring under the Companies' Creditors Arrangement Act (CCAA) in Canada, along with related proceedings in the U.S. and Israel, and secured debtor-in-possession financing.

VBI Vaccines held its 2024 Annual General Meeting, where shareholders elected directors and approved the appointment of EisnerAmper LLP as the company's independent auditor.

VBI Vaccines reports positive interim tumor response data from its Phase 2b study of VBI-1901 in recurrent glioblastoma, showing a 43% disease control rate compared to 0% in the control arm.

VBI Vaccines reports its financial results for the first quarter of 2024, highlighting revenue growth and strategic partnership developments.

VBI Vaccines has entered into a forbearance agreement with its lenders following a failure to meet revenue targets, providing a temporary reprieve from exercising remedies.